No profile data available.
ProQR Therapeutics N.v. (PRQR) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Leiden, Netherlands, with about 186 full-time employees.
It reported revenue of 15.91 million EUR for fiscal year 2025, down 15.9% from fiscal year 2024, and net income of -42.18 million EUR. In Q2 2026 (the quarter ended June 30, 2026) revenue was 8.76 million EUR, up 129.5% from a year before. Its market capitalization was $230.02 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
ProQR Therapeutics reported 15.91 million EUR in revenue for fiscal year 2025, down 15.9% from 18.91 million EUR in fiscal year 2024. In Q2 2026 revenue was 8.76 million EUR.
$230.02 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Probi AB (publ) (PBBIF), Bicycle Therapeutics plc (BCYC), Protara Therapeutics, Inc. (TARA), Tiziana Life Sciences Ltd (TLSA).